Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Atrium starts Cinatra voclosporin coated coronary stent clinical trial

Atrium Medical : 10 June, 2008  (Company News)
Atrium Medical has begun enrollment of the first patients for its CONFIRM 1, First-in-Man (FIM) drug eluting coronary stent clinical trial.
Atrium's European FIM clinical trial study is evaluating Atrium's Cinatra voclosporin coated coronary Stent system.

This First-in-Man trial is a prospective, multi-centre, single blind, randomised, controlled study using the Cinatra voclosporin coated coronary Stent system, which will be compared to Atrium's Cinatra bare metal coronary Stent (BMS) platform.

This first use study of voclosporin on an implantable medical device will enroll 100 patients, and will be conducted at seven hospitals in Belgium with Glenn Van Langenhove, MD, PhD of Middelheim Hospital, Antwerp, as the study's principal investigator.

The primary endpoint of the trial is to evaluate the safety and performance of the Cinatra) voclosporin coated coronary Stent system and the Cinatra BMS coronary Stent system in patients with de novo coronary artery disease. Patient outcomes, in addition to drug coated Stent performance, will be assessed by measuring Late Lumen Loss, in-stent and in-segment lumen loss measurements at six months following implantation.

After many years of pre-clinical testing, Atrium is able to study the new Cinatra coronary Stent platform with voclosporin, a new drug, and the company's natural O3FA coating technology that merges the safety benefits of a bare metal Stent with the clinical advantages of a bio-absorbable Omega 3 fatty acid coating.

Use of Atrium's patented Omega 3 coating platform, together with its novel drug compound has created a new class of patient treatment options who require a drug eluting coronary stent. Interventional cardiologists and patients alike have been waiting for a new technology that delivers the effectiveness of a drug eluting Stent with a safer, more natural, non-polymer coating platform resulting in a well healed Implant shortly after insertion.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo